08/20/2024 | Press release | Distributed by Public on 08/20/2024 06:47
Medtronic announced first-quarter FY25 financial results on Tuesday. Here are three things to know:
A strong start
Our innovative technologies fueled 5.3% organic revenue growth during the first quarter. Notable growth drivers included our Percept™ RC deep brain stimulator, transcatheter aortic heart valves (TAVR), and our MiniMed™ 780G automated insulin delivery (AID) system that treats diabetes.
Innovating for the future
We launched several therapies that will build on our momentum - and benefit patients. Those include Inceptiv™, an advancement in the treatment of chronic pain through spinal cord stimulation therapy, and Evolut™ FX+ TAVR, a therapy for patients with severe aortic stenosis.
Raising our guidance
Following our strong first-quarter performance, we're raising our guidance for the full fiscal year. We now expect organic revenue growth of 4.5% to 5%, and non-GAAP diluted earnings per share of $5.42 to $5.50.
L009-08192024
Related content